Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma

Cancer Journal

Volumn 12, Issue 4, 2006, Pages 299-304

  Tester, William ^a   Ackler, Joann ^a   Tijani, Lukman ^a   Leighton, John ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

Brief Pain Inventory; Docetaxel; FACT P; Hormone refractory prostate cancer; Trial Outcome Index

Indexed keywords

DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEBRILE NEUTROPENIA; HUMAN; HYPERGLYCEMIA; LUNG EMBOLISM; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NEUTROPENIA; PAIN ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; SCORING SYSTEM; STOMATITIS; TREATMENT RESPONSE; VEIN THROMBOSIS;

EID: 33747823814     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200607000-00008     Document Type: Article

References (16)

1. Jemal A, Murray T, Ward W et al. Cancer Statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Berry W, Rohrbaugh T. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001:28[4 suppl 15]:8-15.
3. Petrylak DP, Macarthur RB, O'Connor J et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999;17:958.
4. Savarese D, Halabi S, Hars V et al. A phase II study of docetaxel, estramustine and low dose hydrocortisone in men with hormone refractory prostate cancer. J Clin Oncol 2001;19:250.
5. Sinibaldi VJ, Carducci MA, Moore-Cooper S et al. Phase II evaluation of docetaxel plus one daily oral estramustine phosphate in the treatment of patients with androgen independent prostrate carcinoma. Cancer 2002;94:1457.
6. Koletsky AJ, Guerra ML, Kronish L. Phase II study of vinorelbine and low dose docetaxel in chemotherapy-naïve patients with hormone-refractory prostate cancer. Cancer J 2003;9:286-292.
7. Kreis W, Budman DR, Fetten J et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate cancer. Ann Oncol 1999;10:33.
8. Tannock JF, de Wit R, Berr WR et al. Docetaxel plus prednisone or mitoxantrone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
9. Petrylak DP, Tangem CM, Hussain M et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
10. Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 2001;28[suppl 15]:3-7.
11. Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997;79:196-202.
12. DiLorenzo G, Pizza C, Autorino R et al. Weekly docetaxel and vinorelbine as first line treatment in patients with hormone refractory prostate cancer. Eur Urol 2004;46:712-716.
13. Bubley GJ et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-3467. Erratum in: J Clin Oncol 2000;18:2644.
14. Cella DF. FACT manual (Version 4) 1997. Centers on Outcomes Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University, Evanston, Illinois.
15. Daut R, Cleeland CS, Flanery R. Development of the Wisconsin Brief Pain Inventory to assess pain in cancer and other diseases. Pain 1982;17:197-210.
16. Esper P, Mo F, Chodak G et al. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) Instrument. Urology 1997;50:920-928.